Pavlos Msaouel: Serum CA-125 as a biomarker for Renal Medullary Carcinoma
Pavlos Msaouel, Assistant Professor of Genitourinary Medical Oncology at MD Anderson Cancer Center, shared a post on LinkedIn:
“ Sharing our Clinical Cancer Research work establishing serum CA-125 as a biomarker for Renal Medullary Carcinoma.
This is now the first cancer-associated blood biomarker to become standard of care and used globally for a kidney cancer.
We analyzed primary RMC tumors vs. normal kidney tissue using RNA-seq and ChIP-seq.
MUC16 was among the top upregulated genes, linked to active histone marks (H3K4me3 & H3K27ac). This transcriptional activation explained the observed elevated CA-125 level in patients with RMC.
In a prospective cohort of 47 RMC pts, elevated CA-125 levels was seen in 66% of cases, correlated with metastatic burden & tracked disease progression & metastatic burden.
Functional studies showed SMARCB1 loss drives MUC16 expression, but other factors also modulate this.
Beyond diagnostics, MUC16 is emerging as a therapeutic target.
Re-expressing SMARCB1 in RMC cell lines suppressed MUC16/CA-125. We have activated a clinical trial of MUC16 x CD3 bispecific therapy in SMARCB1-deficient malignancies.
This study establishes CA-125 as a clinically relevant biomarker for RMC, enabling non-invasive disease monitoring.
Future directions include exploring MUC16-targeted therapies, and combiningCA-125 with ctDNA for precision tracking.”
CA-125 as a Biomarker in Renal Medullary Carcinoma: Integrated Molecular Profiling, Functional Characterization, and Prospective Clinical Validation.
Authors: Sandra L. Grimm, et al.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023